Longeveron Inc. will explore strategic options after its experimental stem cell therapy failed a mid-stage trial, sending shares down 60% in after-hours trading on Wednesday evening. The setback halts development for a rare infant heart condition after the treatment missed its primary endpoint. United States regulators will meet with executives as the firm moves to cut costs and pivot toward aging-related frailty research.

Trial Results Disappoint Investors